Personalized NK Cell Therapy in CBT

Phase 2 Recruiting 100 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.

Timeline

Start: 2016-05-19
Primary completion: 2027-05-31
Completion: 2027-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NK-92/5.28.z	Cell therapy	—	Intravenous
Background	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Protein / enzyme biologic	—	Intravenous
Background	Busulfan	Small molecule	—	Intravenous
Background	Clofarabine	Other / unclassified	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Fludarabine	Small molecule	—	Intravenous
Background	Melphalan	Small molecule	—	Intravenous
Background	Rituximab	Monoclonal antibody	—	Intravenous

Personalized NK Cell Therapy in CBT

Summary

Timeline

Drugs

Indications